Best peptides for brain health
Peptides researched for neuroprotection, cognitive enhancement, and neurological recovery.
Neuroprotective peptides target different aspects of brain health — from stimulating nerve growth factors to modulating neurotransmitter systems and reducing neuroinflammation. Some are approved for neurological conditions outside the US, while others remain experimental. Here is an honest look at the evidence.
A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Approved in over 40 countries (but not the US) for stroke recovery, traumatic brain injury, and dementia. It has a significant evidence base but remains controversial in Western neurology.
What evidence supports
- ✓multiple RCTs show modest improvement in cognitive and global function in Alzheimer's patients
- ✓evidence of benefit in acute ischemic stroke recovery in several clinical trials
- ✓approved for neurological indications in over 40 countries including EU member states
Key concern: not FDA-approved — the FDA has not reviewed it for any indication
A 21-amino acid peptide encoded in the mitochondrial genome, discovered in 2001 as a neuroprotective factor. Humanin levels decline sharply with age and in Alzheimer's disease. Emerging research links it to longevity, insulin sensitivity, and cytoprotection — though human data remains preliminary.
What evidence supports
- ✓plasma Humanin significantly lower in Alzheimer's patients vs healthy age-matched controls
- ✓neuroprotection against Aβ toxicity in cell culture and mouse models
- ✓extends lifespan in C. elegans; improves healthspan markers in mice
Key concern: no completed human clinical trials for longevity or cognitive indications
A non-hematopoietic analog of erythropoietin (EPO) engineered to activate the innate repair receptor (IRR) without stimulating red blood cell production. Designed to deliver EPO's tissue-protective and anti-inflammatory properties without cardiovascular risks of hematopoietic EPO. Investigated for diabetic neuropathy and sarcoidosis-associated neuropathy with promising Phase 2 data.
What evidence supports
- ✓Phase 2 RCT (Brines et al., 2014): 67 sarcoidosis patients with small fiber neuropathy — significant improvement in corneal nerve fiber density, neuropathic pain, and autonomic function vs placebo
- ✓Phase 2 data in type 2 diabetes with peripheral neuropathy: improvements in intraepidermal nerve fiber density and neuropathic pain scores
- ✓clean safety profile in completed trials — no erythropoiesis, no thrombotic events
Key concern: not FDA or EMA approved — clinical trials ongoing
A synthetic peptide analog of ACTH (adrenocorticotropic hormone) fragment 4-10, developed in Russia for neuroprotection and cognitive enhancement. Approved in Russia and Ukraine for stroke recovery and cognitive disorders. Popular in the nootropic community worldwide.
What evidence supports
- ✓approved in Russia and Ukraine for stroke recovery and cognitive impairment
- ✓demonstrated neuroprotective effects in ischemic stroke models
- ✓shown to increase BDNF and NGF levels in multiple studies
Key concern: not FDA-approved or recognized by Western regulatory agencies
A synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Gaining interest in Western biohacking communities for anxiety and cognitive support.
What evidence supports
- ✓approved as an anxiolytic medication in Russia based on clinical studies
- ✓demonstrated anxiolytic effects in multiple animal models
- ✓some human studies show reduced anxiety scores, though trials are small
Key concern: not FDA-approved or approved in most Western countries
A synthetic peptide derivative designed to enhance hepatocyte growth factor (HGF) signaling. Developed at Washington State University as a potential cognitive enhancer. Extremely popular in nootropic communities despite being untested in humans.
What evidence supports
- ✓enhanced cognitive performance in aged rats at picomolar concentrations in animal studies
- ✓promoted synaptogenesis in cell culture models
- ✓showed neuroprotective effects in scopolamine-treated rat models of cognitive impairment
Key concern: zero published human clinical trials
A synthetic tripeptide (Glu-Asp-Arg) developed by the Khavinson group at the St. Petersburg Institute of Bioregulation. Designed as a bioregulator for the pineal gland, claimed to support circadian rhythm, cognitive function, and antioxidant defense. Evidence comes primarily from Russian laboratory research with limited independent replication.
What evidence supports
- ✓in vitro: EDR peptide reduces oxidative stress markers in neural cell cultures
- ✓Russian clinical reports: improvements in sleep and cognitive metrics in elderly patients
- ✓animal studies: neuroprotective effects in ischemia models
Key concern: almost all evidence originates from the same Russian research group (Khavinson et al.) with limited independent verification
Not sure which is right for you?
Take our quiz for a personalized recommendation based on your goals and preferences.
Take the Peptide QuizMedical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.